

REVIEW OF DECISIONS

BOARD MEETING

11 May 2020, Teleconference



Reach every child

www.gavi.org

Decision 1: IFFIm COVID Arrangement Proposal

The Gavi Alliance Board considered offering the power of Gavi's innovative finance instruments, notably the International Finance Facility for Immunisation (IFFIm), to support the development of vaccines and:

- a) **Approved** the Assessment Framework set out in Section B.2 to Doc 03 as the basis for determining the Secretariat's response to donors' requests to execute any future transaction that would not have any material adverse impact on Gavi's finances or operations, noting that any transaction that meets all the criteria of the Assessment Framework is deemed an Eligible Transaction;
- b) **Approved** Gavi supporting the Coalition for Epidemic Preparedness Innovations (CEPI) by way of the transaction outlined in Section B.3 to Doc 03 and any other Eligible Transaction for the benefit of CEPI; and
- c) **Noted** that CEPI will be considered as a Gavi Non-Country Specific Programme consistent with IFFIm's requirements.

Decision 2: COVID-19: Gavi's Immediate and Interim Response (1/2)

The Gavi Alliance Board:

- a) **Noted** the authority granted by the Board in March 2020 to the CEO to adjust budget amounts by up to 20% for the purposes set out in the Programme Funding Policy and **granted** the Gavi CEO the authority to adjust and/or exceed the aggregate overall Gavi forecasted amounts for 2020 and 2021 by up to 20% to respond to the COVID-19 pandemic;
- b) **Preserved** countries' eligibility status and co-financing at 2020 levels for 2021 and **granted** the CEO the authority to waive 2020 co-financing obligations on a case-by-case basis upon request by a country;
- c) **Provided guidance** on whether Gavi should play a broader role in helping countries to address their full cold chain needs to respond to COVID-19 and potentially other PHC commodities, recognising that this will require mobilisation of supplementary funding;

Decision 2: COVID-19: Gavi's Immediate and Interim Response (2/2)

- d) **Provided guidance** on whether the three areas of focus for Gavi's engagement in COVID-19 vaccines are appropriate; and
- e) **Granted authority** to the CEO and the Chair of the Board to make decisions on Gavi's co-leadership of the Access to COVID-19 Tools (ACT) Accelerator vaccine pillar. The CEO with the Chair of Board will report on the progress at the June 2020 Board meeting.

Thank you

